Compare SHEN & AQST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SHEN | AQST |
|---|---|---|
| Founded | 1902 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 635.1M | 529.4M |
| IPO Year | 1994 | 2007 |
| Metric | SHEN | AQST |
|---|---|---|
| Price | $12.26 | $4.58 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | ★ $26.00 | $9.00 |
| AVG Volume (30 Days) | 478.6K | ★ 3.2M |
| Earning Date | 05-01-2026 | 05-01-2026 |
| Dividend Yield | ★ 0.73% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $357,854,000.00 | $67,430,000.00 |
| Revenue This Year | $7.12 | $10.08 |
| Revenue Next Year | N/A | $49.60 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 9.08 | 0.77 |
| 52 Week Low | $9.67 | $2.94 |
| 52 Week High | $17.35 | $7.55 |
| Indicator | SHEN | AQST |
|---|---|---|
| Relative Strength Index (RSI) | 43.15 | 66.91 |
| Support Level | $10.94 | $4.03 |
| Resistance Level | $16.89 | $4.69 |
| Average True Range (ATR) | 0.62 | 0.24 |
| MACD | 0.01 | 0.08 |
| Stochastic Oscillator | 26.28 | 87.72 |
Shenandoah Telecommunications Co with its subsidiaries, provides various broadband communication products and services via its wireless, cable, fiber optic, and fixed wireless networks to customers in the Mid-Atlantic United States. The company operates through one business unit: Broadband. The broadband segment provides broadband Internet, video, and voice services to residential and commercial customers. The broadband segment generates the vast majority of the company's revenue, with the bulk of sales flowing from residential and small, and medium businesses within the broadband unit.
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif, and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.